BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, January 16, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

June 5, 2018

View Archived Issues

Mouse models of high-grade bladder cancer for in vivo evaluation of immunotherapy presented

Read More

Bayer Animal Health discovers anthelmintic compounds

Read More

GS-0976 demonstrates significant hepatic effects in patients with NASH cirrhosis

Read More

Hepagene Therapeutics describes farnesoid X receptor agonists

Read More

MALT1-targeting compounds synthesized by the Dana-Farber Cancer Institute and collaborators

Read More

Prelude Therapeutics identifies PRMT5 inhibitors

Read More

Myalepta receives positive CHMP opinion for generalized and partial lipodystrophy

Read More

Cyxone chooses to complete acquisition of rabeximod

Read More

GERD candidate X-842 safe and well tolerated in first-in-human study

Read More

Dynavax Technologies presents Toll-like receptor 7/8/9 antagonists

Read More

First-in-human results from Millennium's TAK-931 in advanced solid tumors

Read More

PFK/FBPase 1 inhibitors identified at Merck KGaA

Read More

Zenith advances trial of ZEN-3694 in metastatic CRPC into phase II

Read More

Evoke submits NDA to the FDA for Gimoti

Read More

FDA accepts NDA filing for bremelanotide for hypoactive sexual desire disorder

Read More

Interim results presented from phase I trial of PIN-2 in patients with solid tumors

Read More

Versartis and Aravive Biologics enter merger agreement

Read More

FDA approves pegfilgrastim biosimilar Fulphila

Read More

FDA clears Nant to begin clinical trials with neoepitope yeast vaccine YE-NEO-011

Read More

Clovis seeks to expand use of Rubraca in E.U. in recurrent ovarian cancer

Read More

Isomer discovery could yield countless new drugs

Read More

Mabion submits MAA for rituximab biosimilar Mabion-CD20

Read More

Perjeta approved in E.U. for adjuvant treatment of HER2-positive early breast cancer

Read More

Yakult licenses rights to duvelisib in Japan

Read More

Primary efficacy endpoint not achieved in phase II study of teslexivir gel in condyloma

Read More

FDA grants priority review to Hemlibra sBLA

Read More

Preclinical study shows Cynata's MSCs are effective in model of diabetic ulcers

Read More

CytRx launches new subsidiary Centurion Biopharma

Read More

Researchers present first-in-human data for Bayer's BAY-1251152 in advanced cancers

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 15, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 15, 2026.
  • SERPINB1 as potential biomarker for spinocerebellar ataxia type 2

    BioWorld Science
    Researchers from Goethe-Universität and collaborators investigated novel molecular biomarker candidates for spinocerebellar ataxia type 2, a progressive...
  • Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

    BioWorld
    With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
  • Businesswoman pressing dollar sign on touchscreen

    JPM 2026: Year kicks off with biopharma Q4 revenue and guidance

    BioWorld
    It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 Healthcare Conference with Alnylam...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing